Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$236.16 USD
+10.67 (4.73%)
Updated May 31, 2024 04:00 PM ET
After-Market: $236.50 +0.34 (0.14%) 6:02 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 141 - 160 ( 184 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: Should You Attend EASL or Not? Yes, Absolutely!
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Confusion Presents Buying Opportunity; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: Kick off EASL with NASH BASH Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NASH Weekly Newsletter: Launch of Our Monthly Clinicaltrials.gov Tracker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly: Who Are The Most Likely Take-Out Candidates in NASH? - Part 2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MGL-3196 Is Jack of All Trades; Reiterate Buy and Raise PT
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Highly Significant Results Across the Lipid Panel in Phase 2 HeFH Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Let the Countdown Begin to HeFH Data; Reaffirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Join Us for Our Spring NASH Bash, with 18 NASH Companies and 6 KOLs
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Imminent Catalyst Alert: We See HeFH as a Low Risk Readout; Raise PT to $156
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: NASH Weekly Newsletter: Oui, Oui, Race to Getting Into EASL Late Breaker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly: Our Best Ideas For 2018 In the NASH Space
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: Who in the NASH Space Had The Best And Worst Year
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y